Advertisement
Journal Home
Search for

Volume 45, Issue 1, Pages 63-68 (January 2009)


View previous. 14 of 18 View next.

The prognostic value of hypoxia markers in T2-staged oral tongue cancer

Jong-Lyel Roha, Kyung-Ja Chob, Gui Young Kwonb, Chang Hwan Ryua, Hyo Won Changa, Seung-Ho Choia, Soon Yuhl Nama, Sang Yoon KimaCorresponding Author Informationemail address

Received 3 February 2008; received in revised form 27 March 2008; accepted 27 March 2008. published online 14 July 2008.

Summary 

Tumor hypoxia is associated with poorer outcome in patients with head and neck carcinomas, but little is known about hypoxia biomarkers in oral tongue cancer. We evaluated whether hypoxia biomarkers and clinicopathologic variables were prognostic predictors in patients with T2-staged squamous cell carcinoma (SCC) of the oral tongue. Tissue microarrays were constructed from formalin-fixed tumor blocks of 43 patients with T2-staged tongue SCCs treated by surgical resection and neck dissection. Tissue samples were stained with monoclonal antibodies to hypoxia-inducible factor (HIF)-1α, HIF-2α, carbonic anhydrase (CA)-9, glucose transporter (GLUT)-1, and erythropoietin receptor (EPOR). Locoregional control and survival rates were calculated by the Kaplan-Meier method, and prognostic factors were calculated from uni- and multivariate analyses. Tumor thickness was correlated with expression of CA-9 and GLUT-1 and nodal classification was correlated with GLUT-1 expression. The nodal metastasis rate was 51%, and the 5-year locoregional control and disease-specific survival (DSS) rates were 59% and 69%, respectively. Univariate analysis showed that HIF-1α and EPOR expression were significantly related to DSS. Multivariate analysis showed that EPOR expression was an independent predictor of DSS (P=0.030). EPOR expression may be an independent predictor for DSS in patients with T2-staged SCC of the oral tongue.

a Department of Otolaryngology, Asan Medical Center, University of Ulsan College of Medicine, 388-1, Pungnap-dong, Songpa-gu, Seoul 138-736, Republic of Korea

b Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Corresponding Author InformationCorresponding author. Tel.: +82 2 3010 3715; fax: +82 2 489 2773.

PII: S1368-8375(08)00100-0

doi:10.1016/j.oraloncology.2008.03.017


View previous. 14 of 18 View next.

Advertisement